10 completed. 10 Phase 1.
By phase and status
Follow nebicapone: new trials by email Literature Review of nebicapone trials Research Report on nebicapone
Trials (filtered) newest first · largest first
All 10 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin
BIA 3-202, warfarin - Healthy | Phase 1 | Completed | 16 | 2006-09-01 | 2017-08-24 |
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
Placebo, BIA 6-512, Madopar® 250 - Parkinson Disease | Phase 1 | Completed | 38 | 2006-07-17 | 2017-03-31 |
Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites
BIA 3-202 (200 mg) - Parkinson's Disease | Phase 1 | Completed | 4 | 2006-01-01 | 2016-05-13 |
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
BIA 3-202, Placebo, Sinemet® - Parkinson's Disease | Phase 1 | Completed | 16 | 2005-09-01 | 2016-05-19 |
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
BIA 3-202, Placebo, levodopa 100 mg / benserazide 25 mg - Parkinson's Disease (PD) | Phase 1 | Completed | 17 | 2005-09-01 | 2016-06-14 |
Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
Nebicapone, Placebo - Parkinson's Disease | Phase 1 | Completed | 22 | 2001-09-01 | 2016-05-13 |
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)
BIA 3-202, Placebo, Sinemet 25/100 - Parkinson's Disease | Phase 1 | Completed | 19 | 2001-04-01 | 2016-05-05 |
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
BIA 3-202, Placebo, Madopar® 125 - Parkinson's Disease | Phase 1 | Completed | 18 | 2001-04-01 | 2016-05-05 |
Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
BIA 3-202, Placebo - Parkinson's Disease | Phase 1 | Completed | 33 | 2000-09-01 | 2016-05-05 |
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202
BIA 3-202, Placebo - Parkinson's Disease | Phase 1 | Completed | 71 | 2000-04-01 | 2016-05-16 |
Conditions studied
Parkinson Disease (9)
Sponsors
Bial - Portela C S.A. (10)
Countries
Portugal (7) · United Kingdom (2) · Switzerland (1)